人工胰腺系统对1型糖尿病患者血糖控制的影响:门诊随机对照试验的系统综述与Meta分析
该系统综述与Meta分析纳入24项门诊随机对照试验共585例1型糖尿病患者,比较人工胰腺系统与常规泵治疗。结果显示人工胰腺系统使目标血糖范围内时间提高12.59%(95%CI 9.02-16.16;p<0.0001),双激素系统较单激素系统改善更明显(19.52% vs 11.06%;p=0.006),但研究间异质性较高。
要点
- 人工胰腺系统使目标范围内时间较常规泵治疗提高12.59%(95%CI 9.02-16.16;p<0.0001)。
- 双激素系统目标范围内时间改善19.52%,单激素系统改善11.06%(p=0.006)。
- 单激素研究异质性I²=79%,高于双激素研究的I²=66%。
核心结论
- 尽管临床和技术因素存在异质性,人工胰腺系统在门诊环境下一致地改善了血糖控制。
研究设计与样本
- 系统综述与Meta分析,检索Medline、Embase和Cochrane对照试验中心注册库自1946年至2017年1月1日发表的文献。
- 纳入24项研究(23项交叉设计、1项平行设计)共27项比较,总计585例1型糖尿病患者(成人研究219例、儿科研究265例、混合研究101例)。
- 比较人工胰腺系统(单纯胰岛素或胰岛素加胰高血糖素)与常规泵治疗(盲法连续血糖监测的持续皮下胰岛素输注或非盲法传感器增强泵治疗)。
- 主要结局为目标血糖范围内时间百分比的均值差,采用随机效应Meta分析;研究注册号PROSPERO 2015:CRD42015026854。
主要发现
- 人工胰腺系统目标范围内时间较常规泵治疗加权均值58.21%提高12.59%(95%CI 9.02-16.16;p<0.0001;I²=84%)。
- 双激素人工胰腺系统目标范围内时间改善19.52%(95%CI 15.12-23.91),单激素系统改善11.06%(95%CI 6.94-15.18),差异p=0.006。
- 7项双激素比较中6项以盲法连续血糖监测的持续皮下胰岛素输注为对照,22项单激素比较中21项以传感器增强泵为对照。
- 单激素研究异质性I²=79%,双激素研究异质性I²=66%。
- 24项研究中12项偏倚评估特征报告不完整,无研究对参与者设盲,结局评估设盲在12项研究中未进行、12项研究中不明确。
局限性
- 24项研究中12项偏倚评估特征报告不完整。
- 无研究对参与者干预分配设盲。
- 结局评估设盲在12项研究中未进行,在12项研究中不明确。
- 单激素研究异质性I²=79%,双激素研究异质性I²=66%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Closed-loop artificial pancreas systems have been in development for several years, including assessment in numerous varied outpatient clinical trials. We aimed to summarise the efficacy and safety of artificial pancreas systems in outpatient settings and explore the clinical and technical factors that can affect their performance. METHODS: We did a systematic review and meta-analysis of randomised controlled trials comparing artificial pancreas systems (insulin only or insulin plus glucagon) with conventional pump therapy (continuous subcutaneous insulin infusion [CSII] with blinded continuous glucose monitoring [CGM] or unblinded sensor-augmented pump [SAP] therapy) in adults and children with type 1 diabetes. We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials for studies published from 1946, to Jan 1, 2017. We excluded studies not published in English, those involving pregnant women or participants who were in hospital, and those testing adjunct medications other than glucagon. The primary outcome was the mean difference in percentage of time blood glucose concentration remained in target range (3·9-10 mmol/L or 3·9-8 mmol/L, depending on the study), assessed by random-effects meta-analysis. This study is registered with PROSPERO, number 2015:CRD42015026854. FINDINGS: We identified 984 reports; after exclusions, 27 comparisons from 24 studies (23 crossover and one parallel design) including a total of 585 participants (219 in adult studies, 265 in paediatric studies, and 101 in combined studies) were eligible for analysis. Five comparisons assessed dual-hormone (insulin and glucagon), two comparisons assessed both dual-hormone and single-hormone (insulin only), and 20 comparisons assessed single-hormone artificial pancreas systems. Time in target was 12·59% higher with artificial pancreas systems (95% CI 9·02-16·16; p<0·0001), from a weighted mean of 58·21% for conventional pump therapy (I2=84%). Dual-hormone artificial pancreas systems were associated with a greater improvement in time in target range compared with single-hormone systems (19·52% [95% CI 15·12-23·91] vs 11·06% [6·94 to 15·18]; p=0·006), although six of seven comparisons compared dual-hormone systems to CSII with blinded CGM, whereas 21 of 22 single-hormone comparisons had SAP as the comparator. Single-hormone studies had higher heterogeneity than dual-hormone studies (I2 79% vs 66%). Bias assessment characteristics were incompletely reported in 12 of 24 studies, no studies masked participants to the intervention assignment, and masking of outcome assessment was not done in 12 studies and was unclear in 12 studies. INTERPRETATION: Artificial pancreas systems uniformly improved glucose control in outpatient settings, despite heterogeneous clinical and technical factors. FUNDING: None.
引用
- Weisman A, Bai JW, Cardinez M, et al. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017. PMID: 28533136. doi:10.1016/S2213-8587(17)30167-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。